Equity Overview
Price & Market Data
Price: $4.30
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $16,354,879
Volume: 0
Performance Metrics
1 Week: 1.42%
1 Month: 3.86%
3 Months: -15.35%
6 Months: -17.15%
1 Year: -59.22%
YTD: -12.78%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD; CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children; and CTx-2103 (buspirone) for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.